Report on the risk assessment of N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF) in the framework of the Council Decision on new psychoactive substances

Series type: Risk assessments

Summary

This publication presents the data and findings of the risk assessment on N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place 4F-iBF in Schedule I of the Single Convention on Narcotic Drugs of 1961 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.

Download as PDF

Table of contents

  • Foreword
  • EMCDDA actions on monitoring and responding to new drugs
  • Europol–EMCDDA Joint Report on 4F-iBF (N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide) — a summary
  • Risk Assessment Report on a new psychoactive substance: N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF)
  • Technical report on N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF)
  • Participants of the risk assessment meeting, 7-8 November 2017

Keywords: 

NPS

Cover of the risk assessment
Pages: 
55
Price: 
free
ISBN: 
978-92-9497-296-5
ISSN: 
1725-4493
Pub. DOI: 
10.2810/64132
Catalog Number: 
TD-AK-18-003-EN-N
Loading